Several tyrosine kinase genes are involved in chromosomal translocations in chronic myeloproliferative disorders, but there are still uncharacterized translocations in some cases. We report two such cases corresponding to atypical chronic myeloid leukaemia with a t(8;9)(p22;p24) translocation. By fluorescence in situ hybridisation (FISH) on the corresponding metaphases with a bacterial artificial chromosome probe encompassing the janus kinase 2 (JAK2) gene at 9p24, we observed a split for both patients, suggesting that this gene was rearranged. The locus at 8p22 contains different candidate genes including the pericentriolar material 1 gene (PCM1), already implicated in reciprocal translocations. The rearrangement of the PCM1 gene was demonstrated by FISH, for both patients. By RT-PCR, we confirmed the fusion of 3 0 part of JAK2 with the 5 0 part of PCM1. Sequence analysis of the chimeric PCM1-JAK2 mRNA suggests that the putative protein displays the coiled-coil domains of PCM1 and the tyrosine kinase domain of JAK2. This new translocation identifies JAK2 as a possible therapeutic target for compounds with antityrosine kinase activity.
Several tyrosine kinase genes are involved in chromosomal translocations in chronic myeloproliferative disorders, but there are still uncharacterized translocations in some cases. We report two such cases corresponding to atypical chronic myeloid leukaemia with a t(8;9)(p22;p24) translocation. By fluorescence in situ hybridisation (FISH) on the corresponding metaphases with a bacterial artificial chromosome probe encompassing the janus kinase 2 (JAK2) gene at 9p24, we observed a split for both patients, suggesting that this gene was rearranged. The locus at 8p22 contains different candidate genes including the pericentriolar material 1 gene (PCM1), already implicated in reciprocal translocations. The rearrangement of the PCM1 gene was demonstrated by FISH, for both patients. By RT-PCR, we confirmed the fusion of 3 0 part of JAK2 with the 5 0 part of PCM1. Sequence analysis of the chimeric PCM1-JAK2 mRNA suggests that the putative protein displays the coiled-coil domains of PCM1 and the tyrosine kinase domain of JAK2. This new translocation identifies JAK2 as a possible therapeutic target for compounds with antityrosine kinase activity. Keywords: atypical chronic myeloid leukaemia; JAK2; PCM1 Among the chronic myeloproliferative disorders, chronic myeloid leukaemia (CML) is a paradigm since it is associated with a reciprocal translocation involving a tyrosine kinase gene, Abelson (ABL) (Heisterkamp et al., 1983) . The t(9;22)(q34;q11) translocation produces a fusion protein BCR-ABL with a tyrosine kinase activity that can be blocked with a small compound, the imatinib mesylate (STI571) (Druker et al., 2001) . In some patients with clinical characteristics of CML (atypical CML), other genes coding for tyrosine kinases such as PDGFRA (Baxter et al., 2002; Trempat et al., 2003) and PDGFRB (Baxter et al., 2003) are implicated.
In this study, we report two cases of atypical CML with the same t(8;9)(p22;p24) translocation. One of the candidate genes involved in this new translocation has a great probability of belonging to a group of genes coding for proteins with tyrosine kinase activity. The janus kinase 2 (JAK2) gene is a good candidate since it is located at 9p24. Indeed, JAK2 has been reported in a few cases of T-ALL (Lacronique et al., 1997) , B-ALL and atypical CML (Peeters et al., 1997) in which it is fused with TEL/ETV6. In addition, several groups (Baxter et al., 2005; James et al., 2005; Levine et al., 2005) have reported that a single acquired activating mutation of JAK2 (Val617Phe) was noted in a majority of patients with polycythaemia vera, essential thrombocytaemia and idiopathic myelofibrosis underlining the role of this kinase in myeloproliferative disorders.
The investigations we carried out were based on the assumption that JAK2 gene was rearranged in the tumour cells of the two patients. They allowed us to characterize a new reciprocal translocation with the fusion of PCM1 at 8p22 with JAK2 at 9p24.
Patient 1, a 46-year-old man, was hospitalized in January 1998 because of asthenia, weight loss and blood abnormalities. On physical examination, the patient displayed pale skin, but no evidence of liver or spleen enlargement. The laboratory results revealed anaemia (haemoglobin ¼ 11.9 g/dl), hyperleucocytosis (WBC ¼ 11.8 Â 10 9 /l) and normal platelets. The leucocyte count showed 28% of immature granulocytes, 2% of erythroblasts but no hypereosinophilia. The bone marrow smears and trephine biopsy confirmed marrow hyperplasia with myelofibrosis but without myelodysplasia. The chromosomal analysis of bone marrow cells showed an isolated t(8;9)(p22;p24) translocation without Philadelphia chromosome. The final diagnosis was atypical CML. The patient was treated with Hydrea, and in August 1998 he received allogenic bone marrow transplantation. After 1 month, he recovered his haematopoiesis, but died in January 1999 from an infectious pneumonia associated with an haemophagocytic syndrome.
Patient 2, a 44 year-old man, was admitted to the hospital in November 2004 after 1-month history of right supra clavicular mass with arm paralysis and chin anaesthesia (Vth cranial nerve). At that time, blood cell counts showed hyperleucocytosis (WBC ¼ 45.8 Â 10 9 /l) with 21% of eosinophils, 30% of immature granulocytes, 4% of blasts and 1% of erythroblasts. Bone marrow aspiration was hypercellular and exibited 54% of myeloblasts with positive peroxydase and 24% of eosinophils. No signs of myelodysplasia were observed. The diagnosis of AML M2 with eosinophilia developed on the setting of an atypical CML was made. Chromosomal analysis revealed an abnormal karyotype with an isolated t(8;9)(p22;p24) translocation. The patient was treated with a combination chemotherapy including Idarubicin and Aracytin associated with meningeal prophylaxis. He achieved a complete remission after a month. The treatment was completed with radiotherapy on solid mass diagnosed at admittance. Different FISH probes specific for ABL and FGFR1 (8p11) were tested and confirmed the lack of rearrangement of these genes in the two cases (data not shown). Therefore, we looked for the presence of candidate genes at 8p22 and 9p24. The examination of the multiple genes reported at 9p24 strongly suggested that JAK2 coding for a tyrosine kinase was involved. In addition, JAK2 had been reported in a t(9;12)(p24;p13) in a few cases of acute lymphoblastic leukaemia and chronic myeloproliferative disorders (Lacronique et al., 1997; Peeters et al., 1997) . For these reasons we tested metaphase chromosomes by FISH with the corresponding JAK2 BAC probe (RP11-927H16) labelled by nick translation with biotin as already reported (Trempat et al., 2003) . In both cases, a split signal was noticed: one part on chromosome 9p24 and the other part at 8p22 (Figure 1, 1a) .
When looking at locus 8p22, it appeared that the best candidate was the pericentriolar material 1 (PCM1) gene, which had been previously described in a reciprocal translocation generating a fusion gene with RET at 10q11 (Corvi et al., 2000) . Therefore, we designed primer sets within the 3 0 coding sequences of JAK2 (corresponding to the TK domain) and within the 5 0 coding region of PCM1 and set up an RT-PCR analysis of total RNA from tumour cells of both patients. A 4 kb product was obtained with patient 1's RNA (Figure 2 ). After sequencing, this product corresponded to a putative 9401 bp mRNA. The structure of the open reading frame of the chimeric PCM1-JAK2 transcript showed that PCM1 exon 37 (NM_006197) was in-frame with JAK2 exon 9 (NM_004972). This structure demonstrates the preservation of all the coiled-coil domains of PCM1 and the tyrosine kinase domain of JAK2 (Figure 3) . The reverse transcript JAK2-PCM1 was detectable with the corresponding primers (Figure 2) . A PCR product of approximately 700 bp was obtained from a 2363 bp long fusion in-frame transcript. As a result of an important degradation of the RNA, RT-PCR remained unsuccessful in patient 2. However, the fusion of PCM1 with JAK2 was confirmed by FISH in both patients (Figures 1b, 2a, b) .
Our results demonstrate that PCM1-JAK2 is a new fusion gene implicated in the development of myeloproliferative disorders. Our cases corresponded to atypical CML in which this abnormality was isolated and thus corresponded to the main oncogenic event. JAK2 is the predominant JAK kinase activated in response to several growth factors and cytokines such as IL-3, GM-CSF and erythropoietin (Barber and D'Andrea, 1994; Carron et al., 2000; Valdembri et al., 2002) . Moreover, JAK2 has been previously implicated in rare cases of T-ALL (Lacronique et al., 1997), B-ALL and atypical CML (Peeters et al., 1997) , and was found to be fused with TEL/ETV6. This fusion gene codes for a chimeric protein with oncogenic properties related to the tyrosine kinase activity of JAK2. TEL/ETV6 belongs to a family of genes with ETS DNA binding domains and helix loop helix domains that allow oligomerisation of these proteins. Indeed, TEL-JAK2 fusion entails a constitutive activation of the tyrosine kinase domains of JAK2 (Lacronique et al., 1997) . It has been shown that this construct was able to induce the growth of Ba/F3 cells in an IL-3-independent manner (Lacronique et al., 1997) . In addition, TEL-JAK2 activates the PI 3 0 -Kinase/AKT pathway (Nguyen et al., 2001) . Interestingly, transgenic mice for TEL-JAK2 develop fatal CD8 þ acute T-cell leukaemia with a constitutive activation of STAT1 and STAT5 (Carron et al., 2000) . Recent publications have reported a high incidence of a single-activating mutation in the JH2 domain of JAK2 (Baxter et al., 2005; James et al., 2005; Levine et al., 2005) . This reinforces the implication of this kinase in the development of myeloproliferative disorders. However, this mutation is mainly observed in chronic myeloproliferative disorders other than CML or atypical CML. The situation is similar for PDGFRA which can be activated by a single mutation in gastroinstestinal stromal tumours (Heinrich et al., 2003) or by a rearrangement in some cases of chronic myeloproliferative disorders (Baxter et al., 2002; Cools et al., 2003; Trempat et al., 2003) . In our study, the partner gene of JAK2 is PCM1 which encodes a 228kD protein containing several potential coiled-coil domains in its amino-terminal part (Balczon et al., 1994) . This protein is localized in cytoplasmic granules referred to as centriolar satellites. Experiments aimed at blocking PCM1 activity with either anti-PCM1 antibodies or small interference RNA lead to a disorderly assembly of centrosomal proteins and microtubules organisation, suggesting that PCM1 plays a pivotal role in these processes (Dammermann et al., 2004) , in particular in the progression of the cell cycle (Balczon et al., 2002) . PCM1 gene corresponds to a chromosomal region frequently lost in cancers (Emi et al., 1992; Bhattacharya et al., 2003) , but its implication in the t(8;10)(p22;q11) translocation in a case of thyroid papillary carcinoma has drawn our attention to its possible implication in chimerical proteins such as PCM1-RET. In addition, its partner in the latter case is a receptor with tyrosine kinase activity (Corvi et al., 2000) .
Since there is a relative ubiquitous expression of PCM1, it is likely that the PCM1 promoter overrides the expression of the PCM1-JAK2 fusion gene, in which the carboxy-terminus corresponds to the catalytic activity of As a result of the presence of multiple coiled-coil domains in the amino-terminal part of PCM1, it is conceivable that the PCM1-JAK2 chimera undergoes an oligomerisation resulting in an activation of the tyrosine kinase domain of JAK2. Further in vitro experiments are needed to confirm that the JAK/STAT and the PI 3 0 -Kinase/AKT pathways are constitutively activated in response to PCM1-JAK2 autophosphorylation.
We described herein two cases of a new translocation variant involving PCM1 and JAK2 genes. The identification of these two partner genes would help in further characterising new cases of myeloproliferative disorders with such a translocation and in monitoring the residual disease after treatment. The clinical presentation of our patients was slightly different, but both had a background of atypical CML. However, one patient was diagnosed in chronic phase without hypereosinophilia while the second was investigated at an acute phase (circulating immature cells from the bone marrow with blast crisis and hypereosinophilia).
In a more prospective point of view, one can suspect that JAK2 will be a good target for new compounds with antityrosine kinase activity.
Note added in proof
During the submission of this manuscript, we have been aware of similar results published by Reiter et al. (2005) . In their report, they found the same PCM1-JAK2 rearrangement in seven patients with identical and distinct breakpoints. Clinically, their patients had atypical CML, chronic eosinophilic leukaemia, secondary acute myeloid leukaemia and pre-B cell acute lymphoblastic leukaemia. However, contrary to our study, they did not find reverse transcripts in all cases.
